Interstitial Lung Disease in Japanese Patients with Lung Cancer
Shoji Kudoh(Japan Anti Tuberculosis Association), Fredrik Nyberg(National Academy of Medicine), Masahiro Tsuboi(National Cancer Center Hospital East), Y. Itoh(AstraZeneca (Japan)), Haiyi Jiang(AstraZeneca (Japan)), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Masahiro Fukuoka(National Institute of Standards and Technology), Harubumi Kato(Tokyo Medical University), Yutaka Nishiwaki(National Cancer Center Hospital East), Tim Higenbottam(AstraZeneca (United Kingdom)), Moritaka Suga(Saiseikai Kumamoto Hospital), Yukito Ichinose(National Hospital Organization Kyushu Cancer Center), Soichiro Yokota(Toneyama National Hospital), Claire Watkins(AstraZeneca (United Kingdom)), Alison Armour(AstraZeneca (United Kingdom)), Kouichiro Nakata
Cited by 488
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k